Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ: FATE) announced the pricing of a public offering of 6,181,562 shares at $28.31 each, aiming to raise approximately $175 million, with expected net proceeds of $164.2 million after fees. The funds will support clinical trials, product manufacturing, and facility expansion. Additionally, the company plans to sell 1,766,160 shares to Johnson & Johnson Innovation for about $50 million. The offering is set to close around June 11, 2020, subject to customary conditions.
Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced an underwritten public offering of its common stock. The funds raised from this offering will support clinical trials, manufacturing operations, and general corporate purposes. The company also anticipates a private placement with Johnson & Johnson Innovation, potentially raising up to $50 million. The offering is subject to market conditions, and underwriters may purchase up to an additional 15% of the shares offered. Fate's innovative therapies target cancer and immune disorders using its advanced stem cell technology.
Fate Therapeutics has received FDA clearance for its Investigational New Drug application for FT538, a novel CRISPR-edited iPSC-derived NK cell therapy. FT538 targets acute myeloid leukemia and multiple myeloma, designed to enhance innate immunity through engineered functionalities. The Phase 1 trial will assess the maximum tolerated dose across 105 patients. This marks the fourth iPSC-derived NK cell product from Fate's platform, aimed at improving treatment efficacy in relapsed cancer patients. The company has begun clinical manufacturing at its San Diego facility.
Fate Therapeutics (NASDAQ: FATE) announced the retirement of Amir Nashat from its board of directors, marking a significant leadership change. Nashat had been a board member since the company's inception in 2007. Robert Hershberg, with extensive experience in immuno-oncology and business development, has been appointed as a new board member. He previously held executive roles at Celgene and VentiRx Pharmaceuticals. The company is focused on advancing its iPSC-derived cell therapies aimed at treating cancer and immune disorders.
Fate Therapeutics (NASDAQ: FATE) will host a conference call on May 11, 2020, at 5:00 p.m. ET to discuss its first quarter 2020 financial results and provide a corporate update. Participants can join by calling 877-303-6235 (domestic) or 631-291-4837 (international), using conference ID 8623509. The event will also be available via a live audio webcast, which can be accessed on the company’s website under "Events & Presentations." Fate Therapeutics focuses on developing programmed cellular immunotherapies for cancer and immune disorders using its proprietary iPSC product platform.